Thirty Madison, an asynchronous telemedicine provider, has raised USD 140 million in a Series C funding round led by new investor HealthQuest Capital along with existing investors including Polaris Partners and Johnson & Johnson Innovation. This brings the company’s total funds raised up to USD 210 million and values the company at USD 1 billion.

The funding will go towards bolstering the company’s proprietary platform capabilities and launching new brands for a wider range of chronic conditions. Thirty Madison also plans to enter the B2B market by partnering with employers and health plans to expand patient reach. It currently covers 40 US states and intends to expand internationally in the long run.

In 2020, the company claimed that its revenue tripled YoY while sales in Q1 2021 exceeded an annual run-rate of USD 100 million. As of May 2021, the company’s telehealth platform had more than 250,000 active members. 

Founded in 2017, Thirty Madison offers direct-to-consumer telehealth consultations, online prescriptions, and treatment delivery for chronic conditions. The specialist treatment is offered for a range of illnesses via four brands; Keeps (for men’s hair loss), Cove (for migraines), Evens (for gastrointestinal conditions), and Picnic (for allergies).